Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Détails
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_AAE7B79746C8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Myeloid-Derived Suppressor-like Cells as a Prognostic Marker in Critically Ill Patients: Insights from Experimental Endotoxemia and Intensive Care Patients.
Périodique
Cells
ISSN
2073-4409 (Electronic)
ISSN-L
2073-4409
Statut éditorial
Publié
Date de publication
08/02/2024
Peer-reviewed
Oui
Volume
13
Numéro
4
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Patients admitted to the intensive care unit (ICU) often experience endotoxemia, nosocomial infections and sepsis. Polymorphonuclear and monocytic myeloid-derived suppressor cells (PMN-MDSCs and M-MDSCs) can have an important impact on the development of infectious diseases, but little is known about their potential predictive value in critically ill patients. Here, we used unsupervised flow cytometry analyses to quantify MDSC-like cells in healthy subjects challenged with endotoxin and in critically ill patients admitted to intensive care units and at risk of developing infections. Cells phenotypically similar to PMN-MDSCs and M-MDSCs increased after endotoxin challenge. Similar cells were elevated in patients at ICU admission and normalized at ICU discharge. A subpopulation of M-MDSC-like cells expressing intermediate levels of CD15 (CD15 <sup>int</sup> M-MDSCs) was associated with overall mortality (p = 0.02). Interestingly, the high abundance of PMN-MDSCs and CD15 <sup>int</sup> M-MDSCs was a good predictor of mortality (p = 0.0046 and 0.014), with area under the ROC curve for mortality of 0.70 (95% CI = 0.4-1.0) and 0.86 (0.62-1.0), respectively. Overall, our observations support the idea that MDSCs represent biomarkers for sepsis and that flow cytometry monitoring of MDSCs may be used to risk-stratify ICU patients for targeted therapy.
Mots-clé
Humans, Endotoxemia, Critical Illness, Prognosis, Myeloid-Derived Suppressor Cells, Critical Care, Endotoxins, biomarker, critically ill patient, endotoxemia, hospital acquired pneumoniae, intensive care, myeloid-derived suppressor cell, sepsis
Pubmed
Web of science
Open Access
Oui
Financement(s)
SNF/Projects/310030_207418
EC/H2020/676129
EC/H2020/847422
OTHER//Fondation Carigest Promex Stiftung für die Forschung
OTHER//Société Académique Vaudoise
Création de la notice
26/02/2024 15:43
Dernière modification de la notice
12/03/2024 8:08